Maximilian Gahr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3057738/publications.pdf

Version: 2024-02-01

		623734	642732
52	669	14	23
papers	citations	h-index	g-index
Γ0	Γ0	Ε0	0.42
58	58	58	843
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Incidence of inpatient cases with mental disorders due to use of cannabinoids in Germany: a nationwide evaluation. European Journal of Public Health, 2022, 32, 239-245.	0.3	7
2	The state of mental health care in China. Asian Journal of Psychiatry, 2022, 69, 102975.	2.0	24
3	Psychological Distress, Fear and Coping Strategies During the Second and Third Waves of the COVID-19 Pandemic in Southern Germany. Frontiers in Psychiatry, 2022, 13, 860683.	2.6	17
4	Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany. European Journal of Clinical Pharmacology, 2021, 77, 767-775.	1.9	7
5	Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey. Expert Opinion on Drug Safety, 2021, 20, 979-985.	2.4	5
6	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. Drugs - Real World Outcomes, 2021, 8, 547-554.	1.6	3
7	Rediscovering Psilocybin as an Antidepressive Treatment Strategy. Pharmaceuticals, 2021, 14, 985.	3.8	8
8	Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection. Frontiers in Psychiatry, 2021, 12, 727687.	2.6	3
9	Harmonization of summaries of product characteristics (SmPCs) of drugs with the same active ingredients: an evaluation of SmPCs of the most frequently prescribed active substances. European Journal of Clinical Pharmacology, 2021, , 1.	1.9	O
10	Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry, 2020, 53, 51-59.	3.3	18
11	Relation of Promoter Methylation of the Oxytocin Gene to Stressful Life Events and Depression Severity. Journal of Molecular Neuroscience, 2020, 70, 201-211.	2.3	17
12	Depressive Disorder With Panic Attacks After Replacement of an Intrauterine Device Containing Levonorgestrel: A Case Report. Frontiers in Psychiatry, 2020, 11, 561685.	2.6	5
13	Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine. Frontiers in Psychiatry, 2020, 11, 32.	2.6	3
14	Takotsubo Cardiomyopathy With Inconspicuous Initial Electrocardiogram: A Potentially Serious Cardiac Pathology Related to Emotional Stress. Frontiers in Psychiatry, 2019, 10, 308.	2.6	2
15	Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions. Brain Sciences, 2019, 9, 322.	2.3	3
16	Lithium Therapy Associated With Renal and Upper and Lower Urinary Tract Tumors. Journal of Clinical Psychopharmacology, 2019, 39, 530-532.	1.4	3
17	Psychiatrists' and dentists' knowledge and attitudes regarding adverse drug reactions of psychotropic drugs. Psychiatry Research, 2018, 266, 323-327.	3.3	2
18	First-Episode Psychosis Possibly due to Roxithromycin-Related Inhibition of Metabolization of Tetrahydrocannabinol. Journal of Clinical Psychopharmacology, 2017, 37, 369-370.	1.4	2

#	Article	IF	CITATIONS
19	Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. Journal of Substance Abuse Treatment, 2017, 74, 7-15.		5
20	Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. International Journal of Molecular Sciences, 2017, 18, 101.	4.1	3
21	Mild Hypothermia in a Child with Low-Dose Risperidone. Zeitschrift FÜr Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2017, 45, 335-337.	0.7	10
22	Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants. primary care companion for CNS disorders, The, 2017, 19, .	0.6	1
23	Survival of Very High Blood Alcohol Concentration Without Consequential Damage in a Patient Without a Previous Substance Use Disorder. Journal of Forensic Sciences, 2016, 61, 1155-1157.	1.6	4
24	Drugâ€Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms. Journal of Clinical Pharmacology, 2016, 56, 769-778.	2.0	13
25	Linking Annual Prescription Volume of Antidepressants to Corresponding Web Search Query Data. Journal of Clinical Psychopharmacology, 2015, 35, 681-685.	1.4	15
26	Periventricular white matter lesion and incomplete MRZ reaction in a male patient with anti-N-methyl-D-aspartate receptor encephalitis presenting with dysphoric mania. BMJ Case Reports, 2015, 2015, bcr2014209075-bcr2014209075.	0.5	7
27	Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre. Journal of Clinical Pharmacology, 2015, 55, 768-773.	2.0	9
28	From benzodiazepine to pregabalin dependence: Different agents, similar problems. Indian Journal of Psychiatry, 2015, 57, 111.	0.7	6
29	Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Research, 2015, 229, 257-263.	3.3	17
30	Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity. Current Drug Metabolism, 2015, 15, 694-702.	1.2	23
31	Abuse liability of centrally acting non-opioid analgesics and muscle relaxants – a brief update based on a comparison of pharmacovigilance data and evidence from the literature. International Journal of Neuropsychopharmacology, 2014, 17, 957-959.	2.1	9
32	Safety of Electroconvulsive Therapy in the Presence of Cranial Metallic Objects. Journal of ECT, 2014, 30, 62-68.	0.6	22
33	Rapid relapse in depression following initialization of oral contraception with ethinyl estradiol and chlormadinone acetate. General Hospital Psychiatry, 2014, 36, 230.e1-230.e2.	2.4	2
34	Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reactions. Psychiatry Research, 2014, 215, 252-254.	3.3	31
35	Pregabalin and addiction: lessons from published cases. Journal of Substance Use, 2014, 19, 448-449.	0.7	5
36	Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks. Current Neuropharmacology, 2014, 12, 387-398.	2.9	29

3

#	Article	IF	Citations
37	Pregabalin abuse and dependence in Germany: results from a database query. European Journal of Clinical Pharmacology, 2013, 69, 1335-1342.		109
38	Electroconvulsive therapy in patients with diagnoses other than major depression and/or difficult characteristics: A combined psychiatric–anesthesiological approach based on a retrospective chart analysis. Psychiatry Research, 2013, 210, 159-165.	3.3	1
39	Cerebral amyloidal angiopathyâ€"A disease with implications for neurology and psychiatry. Brain Research, 2013, 1519, 19-30.	2.2	36
40	Intoxications with the monoamine oxidase inhibitor tranylcypromine: An analysis of fatal and non-fatal events. European Neuropsychopharmacology, 2013, 23, 1364-1372.	0.7	10
41	Concerns About Pregabalin. Journal of Addiction Medicine, 2013, 7, 147-149.	2.6	51
42	Abuse liability of flupirtine revisited: Implications of spontaneous reports of adverse drug reactions. Journal of Clinical Pharmacology, 2013, 53, 1328-1333.	2.0	11
43	Dependence on Flupirtine. Journal of Clinical Pharmacology, 2013, 53, 1003-1004.	2.0	6
44	Self-mutilation induced by psychotropic substances: A systematic review. Psychiatry Research, 2012, 200, 977-983.	3.3	18
45	"Krokodilâ€â€"Revival of an Old Drug with New Problems. Substance Use and Misuse, 2012, 47, 861-863.	1.4	20
46	Cognitive Impairment and Abnormal Behaviour Related to Ring Chromosome 20 Aberration. Journal of Autism and Developmental Disorders, 2012, 42, 1146-1148.	2.7	7
47	Protracted delirium with Sheehan's syndrome. Acta Neuropsychiatrica, 2012, 24, 183-185.	2.1	3
48	Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report. Journal of Medical Case Reports, 2012, 6, 49.	0.8	2
49	Paliperidone extended-release: does it have a place in antipsychotic therapy?. Drug Design, Development and Therapy, 2011, 5, 125.	4.3	20
50	Somatization Disorder Treated With Electroconvulsive Therapy. Journal of ECT, 2011, 27, 266-267.	0.6	5
51	Non-suicidal self-injury by intravenous application of nicotine in a patient with borderline personality disorder resulting in substance dependence. Addiction, 2011, 106, 1186-1187.	3.3	1
52	Neuroleptic malignant syndrome with aripiprazole in Huntington's disease. Movement Disorders, 2010, 25, 2475-2476.	3.9	7